Incretins|Based Therapies and Their Cardiovascular Effects

Incretins-Based Therapies and Their Cardiovascular Effects - NCBI

This comprehensive review specifically concentrates on these cellular and molecular processes mediating the cardiovascular effects of incretins-like molecules.

Incretins-Based Therapies and Their Cardiovascular Effects - PubMed

Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists ...

Cardiovascular Effects of Incretin-Based Therapies

Incretin hormones, including GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), are gut hormones secreted ...

Cardiovascular Actions of Incretin-Based Therapies - AHA Journals

Improved understanding of the complex science of incretin-based therapies is required to optimize the selection of these therapeutic agents for ...

Cardiovascular Effects of Incretin-Based Therapies - Annual Reviews

These agents prolong the action of the incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), by inhibiting their breakdown. The ...

Cardiovascular effects of incretin-based therapies in patients with ...

Incretin-based therapies did not have an increased cardiovascular risk compared with other traditional antidiabetic drugs in both pairwise and network meta- ...

Cardiovascular Effects of Incretin-Based Therapies

As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of debilitating cardiovascular complications.

Effect of Long-term Incretin-Based Therapies on Ischemic Heart ...

Several studies have demonstrated the cardioprotective effects of incretin-based therapies; however, there are few studies on the effects of ...

Understanding the Cardiovascular Effects of Incretin

Incretin, especially the GLP-1-based compounds, appears to have cardioprotective potential independent of weight loss and glycemic control.

Cardiovascular Biology of the Incretin System - Oxford Academic

Incretin-based agents control body weight, improve glycemic control with a low risk of hypoglycemia, decrease blood pressure, inhibit the secretion of ...

Cardiovascular Outcome Trials of the Incretin-Based Therapies

Results: Independent of their glucose-lowering action, incretin-based therapies may have incretin-dependent mechanisms that positively affect blood pressure, ...

Cardiovascular effects of the incretin‐based therapy: the good, the ...

Incretin-based therapy does not increase the risk of cardiovascular events in general. However, the risk of hospital admission for heart failure ...

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Treatment with GLP-1RAs rapidly reduces plasma triglyceride and LDL-cholesterol levels, even in the presence of statins [25]. GLP-1RAs also ...

Cardiovascular consequences of drugs used for the treatment of ...

Two new classes of diabetic drugs targeting the glucagon-like peptide-1 (GLP-1) incretin pathway have emerged. The GLP-1 receptor agonists reduce blood glucose ...

The cardiovascular safety of incretin-based therapies: a review of ...

There is mechanistic evidence to suggest that GLP-1 receptor agonists may confer cardioprotective effects following ischaemia. Retrospective ...

Achieving equitable access to incretin-based therapies in ...

Based on the preponderance of growing evidence, GLP1RAs are now a cornerstone in the treatment of T2DM [7]. Incretin hormones are crucial for glucose ...

Cardiovascular Effects of Incretin Therapy in Diabetes Care

Many phase 2 and 3 trials and retrospective analyses showed improvement in cardiovascular risk factors and outcomes. However, there are data ...

Is the Way to Someone's Heart Through Their Stomach? | Circulation

An intriguing feature of incretin-based drugs is their effect on the kidney. Whereas insulin and thiazolidinediones cause sodium retention, both ...

The non-glycemic effects of incretin therapies on cardiovascular ...

The incretin therapies, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors, have been developed to lower blood ...

Incretin-based agents in type 2 diabetic patients at cardiovascular risk

When we evaluated the combined effect of six trials, the results suggested that incretin-based treatment had no significant effect on overall ...